New Sleep Apnea Solution

Two existing medications are remodelled for treating sleep apnea can reduce the severity of disease by at least 30 per cent. This breakthrough in drug therapy helps sleep apnea treatment in long run.

Giving new purpose to two existing medications in sleep apnea treatment can reduce at least 30 per cent of severity in people.

Sleep apnea is a condition where the upper airway from the back of the nose to the throat closes repetitively during sleep that restricts oxygen intake and wake up people as often as 100 times or more per hour. It affects around 1.5 million adults in the UK.

Obstructive Sleep Apnea - Overview
Obstructive sleep apnea should be suspected in overweight middle aged adults who snore loudly and which can cause interruption of breathing for 10 seconds or more and this results in reduced blood o

‘Medications like reboxetine and butyl bromide improve sleep apnea treatment outcomes.’

Untreated sleep apnea can cause cardiovascular disease, dementia and depression. People with sleep apnea are two to four times more likely to crash a car than the general population.

Currently, the main therapy for sleep apnea is wearing a mask to bed, or Continuous Positive Airway Pressure Therapy (CPAP), which many people feel troublesome and hard to tolerate.

The efficacy of second line therapy like mouthguards fitted by dentists can be unpredictable and expensive. There are no approved drug therapies to treat the condition despite thirty years of research.

Dronabinol: Anti-Nausea Drug to Treat Sleep Apnea
A new study has found dronabinol an anti-nausea drug could help to treat sleep apnea.

The new research published in The Journal of Physiology evaluated the efficacy of reusing existing medications in people with sleep apnea.

Previous research showed two classes of medication, reboxetine and butyl bromide keep muscles active during sleep in people without sleep apnoea, and assist their ability to breathe.

Sleep Apnea can Lead to Cognitive Decline in Older Men
Sleep warning for older men - disruption or change in sleeping patterns can lead to cognitive decline.

By repurposing the medications, the researchers at Flinders University used a multitude of recording instruments to measure whether reboxetine and butyl bromide can successfully target the main causes of sleep apnea.

This includes balancing the electrical activity of muscles around the airway, preventing the throat from collapsing while people were sleeping, and improving the regulation of carbon dioxide and breathing during sleep.

Excess Tongue Fat may Lead to Sleep Apnea
Losing tongue weight might be an effective way to manage obstructive sleep apnea, a condition that affects an estimated 22 million Americans.

The Results of the study show that these medications increased the muscle activity around the airways, and reduced one third of the sleep apnea severity.

"We were thrilled because the current treatment options for people with sleep apnea are limited and can be a painful journey for many, Next we will look at the effects of these and similar medications over the longer term” said Professor Eckert, Principal Research Scientist at NeuRA and Professor and Director of Adelaide Institute for Sleep Health at Flinders University.

People's oxygen intake improved and their number of breathing stoppages were less. All the participants showed some improvement in sleep apnea.

These new findings allow researchers to further refine these types of medications so that they have greater benefit and these treatments can be combined with other existing medications to improve their efficacy.

Source-Medindia